JP5219147B2 - 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 - Google Patents
色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 Download PDFInfo
- Publication number
- JP5219147B2 JP5219147B2 JP2008532133A JP2008532133A JP5219147B2 JP 5219147 B2 JP5219147 B2 JP 5219147B2 JP 2008532133 A JP2008532133 A JP 2008532133A JP 2008532133 A JP2008532133 A JP 2008532133A JP 5219147 B2 JP5219147 B2 JP 5219147B2
- Authority
- JP
- Japan
- Prior art keywords
- mizoribine
- cells
- synovitis
- pigmented
- cell tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
(2)細胞+medium +LPS 10μg/mLで刺激
(3)細胞+medium +TNFα 1000U/mLで刺激
(4)細胞+medium IL−1β 1000U/mLで刺激
(6)細胞+medium +LPS 10μg/mLで刺激
(7)細胞+medium +TNFα 1000U/mLで刺激
(8)細胞+medium IL−1β 1000U/mLで刺激
(10)細胞+medium +TNFα 1000U/mLで刺激
(11)細胞+medium IL−1β 1000 U/mLで刺激
2.IL−1β(1000U/mL)
3.IL−1β(1000U/mL)+ミゾリビン(10μg/mL)
Lysis buffer:50mM Tris−HCl(pH7.5)、150mM NaCl、1% TritonX−100、10mM−β−グリセロホスフェート、1mM オルトバナジン酸ナトリウム、1% プロテアーゼインヒビターカクテル、1mM フェニルメチルスルホニルフルオリド(PMSF)/エタノール。但し、PMSFは使用直前に添加。
Sample buffer:10% シュークロース、5% 2−メルカプトエタノール、2% SDS、62.5mM Tris−HCl(pH6.8)、1% ブロモフェノールブルー(数滴)。
Running buffer:25mM Tris、192mM グリシン、0.1% SDS。
Transfer buffer:25mM Tris、192mM グリシン、20% メタノール。
TBS−T:13.7mM NaCl、0.268mM KCl、25mM Tris、0.05% Tween20。
Blocking buffer:5%スキムミルク/TBS−T。
Claims (2)
- ミゾリビンを含有する色素性絨毛結節性滑膜炎及び/又は腱鞘骨巨細胞腫の治療薬。
- 前記ミゾリビンを50mg以上1g以下の範囲内で含んでなる請求項1記載の治療薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008532133A JP5219147B2 (ja) | 2006-09-01 | 2007-08-31 | 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006237156 | 2006-09-01 | ||
JP2006237156 | 2006-09-01 | ||
PCT/JP2007/067030 WO2008026729A1 (fr) | 2006-09-01 | 2007-08-31 | Agent thérapeutique pour une synovite villonodulaire pigmentée ou une tumeur à cellules géantes de la gaine tendineuse ou de l'os |
JP2008532133A JP5219147B2 (ja) | 2006-09-01 | 2007-08-31 | 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2008026729A1 JPWO2008026729A1 (ja) | 2010-01-21 |
JP5219147B2 true JP5219147B2 (ja) | 2013-06-26 |
Family
ID=39136010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008532133A Expired - Fee Related JP5219147B2 (ja) | 2006-09-01 | 2007-08-31 | 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5219147B2 (ja) |
WO (1) | WO2008026729A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013146435A1 (ja) | 2012-03-26 | 2013-10-03 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤 |
KR20220000993A (ko) | 2013-09-25 | 2022-01-04 | 닛뽕 케미파 가부시키가이샤 | 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골 |
-
2007
- 2007-08-31 WO PCT/JP2007/067030 patent/WO2008026729A1/ja active Application Filing
- 2007-08-31 JP JP2008532133A patent/JP5219147B2/ja not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
JPN6012059037; Kobe J. Med. Sci. Vol.47, No.1, 2001, pp.13-23 * |
JPN6012059040; Curr. Med. Chem. Vol.6, No.7, 1999, pp.575-597 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008026729A1 (ja) | 2010-01-21 |
WO2008026729A1 (fr) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Adamopoulos et al. | Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors | |
Garcia-Velasco et al. | Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis | |
Jimi et al. | Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo | |
Moschen et al. | Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease | |
Gonçalves et al. | Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel | |
AU2014229985B2 (en) | Methods of treating colorectal cancer | |
US10006029B2 (en) | Methods of treating colorectal cancer | |
Wong et al. | Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget’s disease | |
CN110772504B (zh) | 刺甘草查尔酮作为抑制剂的用途 | |
Wang et al. | GDF11 antagonizes psoriasis-like skin inflammation via suppression of NF-κB signaling pathway | |
Bittermann et al. | Oral ibuprofen interferes with cellular healing responses in a murine model of Achilles tendinopathy | |
JP2021106625A (ja) | Il−34アンチセンスオリゴヌクレオチドおよびその使用方法 | |
Huang et al. | USP13 mediates PTEN to ameliorate osteoarthritis by restraining oxidative stress, apoptosis and inflammation via AKT-dependent manner | |
Wang et al. | Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide-induced osteoporosis by inhibiting osteoclast formation | |
Xu et al. | Small molecule natural compound targets the NF‐κB signaling and ameliorates the development of osteoarthritis | |
Ouyang et al. | The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice | |
JP5219147B2 (ja) | 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬 | |
Portnoy et al. | Alveolar type II cells inhibit fibroblast proliferation: role of IL-1α | |
JP2017081870A (ja) | 椎間板変性症に対する治療薬jak‐stat3阻害剤 | |
Cai et al. | Paeoniflorin‐6′‐o‐benzene sulfonate (CP‐25) improves vasculitis through inhibiting IL‐17A/JAK/STAT3 signaling pathway in endothelial cells of HFD CIA rats | |
Lau et al. | Malignant melanoma and bone resorption | |
CN113616652A (zh) | Sms2抑制剂在制备治疗高侵袭性乳腺癌药物中的应用 | |
Ren et al. | IL-37 alleviates liver granuloma caused by Schistosoma japonicum infection by inducing alternative macrophage activation | |
Boby et al. | Identification, Characterization, and Transcriptional Reprogramming of Epithelial Stem Cells and Intestinal Enteroids in Simian Immunodeficiency Virus Infected Rhesus Macaques | |
WO2023171789A1 (ja) | Vla-4の阻害物質を含む、心筋炎を予防、又は治療するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100830 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121112 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130228 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160315 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |